129493-70-5

Basic information

• Product Name: Butanoic acid, 2-[(2,4-dichlorophenyl)hydrazono]-3-oxo-, ethyl ester
• CAS NO: 129493-70-5
• Molecular Formula: C12H12Cl2N2O3
• Molecular Weight: 303.145
• Mol File: 129493-70-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Butanoic acid, 2-[(2,4-dichlorophenyl)hydrazono]-3-oxo-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 2-[(2,4-dichlorophenyl)hydrazono]-3-oxo-, ethyl ester(129493-70-5)
• EPA Substance Registry System: Butanoic acid, 2-[(2,4-dichlorophenyl)hydrazono]-3-oxo-, ethyl ester(129493-70-5)

Safety Data

• Hazardous Substances Data: 129493-70-5(Hazardous Substances Data)

Upstream product

• 141-97-9 ethyl acetoacetate 
• 554-00-7 2,4-Dichloroaniline 

Downstream Products

• 27143-12-0 ethyl chloro[(2,4-dichlorophenyl)hydrazono]acetate 
• 1620683-71-7 1-(2,4-dichlorophenyl)-4-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid 
• 1633819-04-1 C₁₂H₇Cl₃N₂O₂ 
• 1620684-04-9 1-(2,4-dichlorophenyl)-N-(3-fluoro-4-((6-methoxy-7-(3-(4-methylpiperidin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-4-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide 
• 1620683-96-6 1-(2,4-dichlorophenyl)-N-(3-fluoro-4-((6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-4-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide 
• 1620683-65-9 ethyl 1-(2,4-dichlorophenyl)-4-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate 
• 1217526-80-1 1-{4-[(2,4-dichlorophenyl)diazenyl]-5-hydroxy-3-methyl-1H-pyrazol-1-yl}-2-(naphthalen-2-yloxy)ethanone 

Relevant articles and documents

Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists

Chemokine receptor 2 (CXCR2) is the receptor of glutamic acid–leucine–arginine sequence-contained chemokines CXCs (ELR+ CXCs). In recent years, CXCR2-target treatment strategy has come a long way in cancer therapy. CXCR2 antagonists could block

Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing pyridazinone moiety as potential antitumor agents

A series of novel 4-phenoxyquinoline derivatives containing pyridazinone moiety were synthesized and evaluated for their in vitro cytotoxic activity against five cancer cell lines (HT-29, H460, A549, MKN-45, and U87MG). Most of the compounds exhibited moderate-to-significant cytotoxicity and high selectivity against one or more cell lines. Compounds 15a, 20a, 15b, 15c, 20d, and 16e were further examined for their inhibitory activity against c-Met kinase. The most promising compound 15a (c-Met half-maximal inhibitory concentration [IC50] = 2.15 nM) showed remarkable cytotoxicity against HT-29, H460, and A549 cell lines with IC50 values of 0.10 μM, 0.13 μM, and 0.05 μM, respectively, and thus it was 1.5- to 2.3-fold more potent than foretinib. Their preliminary structure-activity relationships (SARs) studies indicate that electron-withdrawing groups on the terminal phenyl rings are beneficial for improving the antitumor activity.